Home>Topics>Companies>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies

    Headlines

    Tue, 12 Aug 2014

    chemotherapy, surgery, and radiation. Investors associate cancer immunotherapy with forerunner Dendreon Corporation (NASDAQ: DNDN ), whose PROVENGE vaccine shocked health plans with its exorbitant price that only extended life a few months

  2. More on Dendreon Q2 results

    Headlines

    Tue, 12 Aug 2014

    Dendreon ( DNDN -33.5% ) Q2 results : Revenues: $82.2M (+12.1%); Operating Expenses: $83.9M (-34.7%); Net Loss

  3. Dendreon beats by $0.10, revenue in-line

    Headlines

    Tue, 12 Aug 2014

    Dendreon (NASDAQ: DNDN ): Q2 EPS of -$0.10 beats by $0.10 . Revenue of $82.2M (+12.1% Y/Y) in-line. Shares -22.6% PM. Press Release Post your comment!

  4. New Morningstar Analyst Report for Dendreon Corp

    Stock Reports

    Tue, 12 Aug 2014

    Dendreon ’s high debt load and ..... viability uncertain. Dendreon 's limited sales and ..... know-how may hamper Provenge 's uptake, and its ..... immunotherapy for cancer, Provenge represents a nontoxic ..... treatments on the market. Provenge was recently approved ..... stewardship rating for Dendreon until we see evidence

  5. Second-Quarter Provenge Sales Are Solid; Convertible Debt Overhang Underscores Serious Risks

    Commentary

    Tue, 12 Aug 2014

    Dendreon reported second-quarter results ..... than our expectations, with solid Provenge sales. However, the ongoing lack ..... moat, negative trend ratings. Dendreon reported $82.2 million in Provenge sales for the quarter, a solid

  6. New Morningstar Analyst Report for Seattle Genetics Inc

    Stock Reports

    Fri, 1 Aug 2014

    investment community (given the recent failure of Dendreon 's pricey prostate cancer drug to live up ..... community following the recent failure of Dendreon 's DNDN pricey prostate cancer drug Provenge to live up to sales expectations. Although

  7. Another Quarter of Sluggish Provenge Sales; Convertible Debt Overhang Underscores Risks

    Commentary

    Fri, 9 May 2014

    Dendreon reported first-quarter results ..... expectations, with continued sluggish Provenge sales and lack of clarity on plans ..... moat, negative trend ratings. Dendreon reported $68.8 million in Provenge sales for the quarter, a slight

  8. Dendreon 4Q Results Show Stabilization of Sales and Highlight European Opportunity; Maintaining FVE

    Commentary

    Mon, 3 Mar 2014

    Dendreon reported fourth-quarter results ..... expectations. The stabilization of Provenge revenue and the announcement of the ..... estimate and our no-moat rating. Dendreon reported $74.8 million in Provenge sales for the quarter, up 10

  9. Dendreon shares jump on news of prostate drug's European launch

    Headlines

    Mon, 3 Mar 2014

    (Reuters) - Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.

  10. Dendreon's 4Q Provenge Sales Slightly Better Than Expected; Maintaining Fair Value Estimate

    Commentary

    Mon, 13 Jan 2014

    Dendreon on Monday announced preliminary Provenge revenue for the fourth quarter ..... increasing competition in Provenge 's prechemotherapy indication ..... the current trajectory of Provenge 's sales, we think Dendreon will need to tap the equity

« Prev12345Next »
Content Partners